Cervical cancer is second to breast cancer as the most common form of malignancy in both incidence and mortality for women worldwide. The pap smear test and liquid-based cytology have been adopted as population-wide cervical cancer screening programs in the U.S.and other developed countries. In the US, this screening program has led to a remarkable reduction in the incidence and mortality rate of cervical cancer, from 26,000 in 1941 to 4,600 in 2000. However, the current method of cervical cancer screening is still subjective and labor intensive in the detection of abnormal cells from large number of normal cells. This application proposes a new approach of involving specific biomarkers and high throughput flow cytometry for the detection of rare abnormal cells. Abnormal cells will be captured and separated from normal cells using flow sorting and based on their expression levels of precancerous biomarkers. The development of this technology could lead to a high throughput, biomarker driven clinical device for routine cervical cancer screening in the future.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA125370-02
Application #
7383854
Study Section
Enabling Bioanalytical and Biophysical Technologies Study Section (EBT)
Program Officer
Patriotis, Christos F
Project Start
2006-12-18
Project End
2009-11-30
Budget Start
2007-12-03
Budget End
2009-11-30
Support Year
2
Fiscal Year
2008
Total Cost
$204,123
Indirect Cost
Name
Purdue University
Department
Other Basic Sciences
Type
Schools of Veterinary Medicine
DUNS #
072051394
City
West Lafayette
State
IN
Country
United States
Zip Code
47907
Thobe, M N; Gurusamy, D; Pathrose, P et al. (2010) The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells. Oncogene 29:214-26
Ling, Jian; Wiederkehr, Urs; Cabiness, Spring et al. (2008) Application of flow cytometry for biomarker-based cervical cancer cells detection. Diagn Cytopathol 36:76-84